3상모집 중단 (진행 중)
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
연구 개요
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
- 스폰서
- 리드: 애브비
- 적응증
- Rheumatoid Arthritis
- 중재
- Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib
- 목표 등록
- 1,629명
- 시작일
- 2015-12-01
- 완료(예정)
- 2027-09-30
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.